GlassScriptPhysician profile
Gregory D Calone
NPI 1538536214
$5,509.93
in general payments reported to CMS, 2019-2025
16 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $324 · 2022: $618 · 2023: $1,433 · 2024: $1,543 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,467.73 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,505.87 | 2021-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $1,355.86 | 2021-2025 | Yeztugo, Biktarvy, Veklury |
| Merck Sharp & Dohme LLC | $415.21 | 2021-2025 | Pifeltro, Dificid, Delstrigo |
| Paratek Pharmaceuticals, INC. | $275.88 | 2022-2024 | Nuzyra |
| Janssen Products, LP | $159.00 | 2021 | |
| Janssen Biotech, INC. | $146.00 | 2021-2023 | Symtuza |
| Astellas Pharma US INC | $130.67 | 2023-2024 | Cresemba |
| Abbvie INC. | $124.13 | 2021-2025 | |
| Melinta Therapeutics, LLC | $115.51 | 2023-2025 | Kimyrsa, Orbactiv, Vabomere |
| Insmed, INC. | $99.07 | 2023-2025 | Arikayce, Brinsupri |
| Aimmune Therapeutics, INC. | $50.46 | 2025 | Zenpep |
| Shionogi INC | $40.61 | 2023 | Fetroja |
| Theratechnologies INC. | $40.08 | 2023-2025 | Egrifta, Trogarzo |
| Dynavax Technologies Corporation | $19.65 | 2025 | Heplisav-B |
| Napo Pharmaceuticals INC | $18.22 | 2023 | Mytesi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $13.71 | 2025 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Calone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.